Status:

RECRUITING

Ketamine, SGB and Combination Treatment for TBI

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

Walter Reed National Military Medical Center

Lviv National Medical University

Conditions:

Posttraumatic Headache

Posttraumatic Stress Disorder

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Post-Traumatic Stress Disorder (PTSD) and traumatic brain injury (TBI) with associated headache are amongst the most common injuries sustained by our deployed forces in Iraq and Afghanistan, as well a...

Detailed Description

This is a multicenter randomized, double-blind (subject, evaluator) placebo-controlled parallel-group clinical trial where 175 eligible subjects will be randomized into 1 of 4 groups (described below)...

Eligibility Criteria

Inclusion

  • Adults 18 years or older
  • Stable doses of medications for \> 2 weeks for TBI and/or PTSD
  • For TBI-associated headache with or without PTSD: HIT-6 score of \>/=53. For PTSD with or without TBI-associated headache: PCL-5 score \>/=33 OR. For those with TBI and PTSD, and a HIT-6 score \< 53 and PCL-5 score of \<33, individuals with a HIT-6 score of 50-52 and a PCL-5 score of 31 or 32 will be included.
  • Duration of chronic TBI or PTSD \> 3 months

Exclusion

  • Ketamine infusion or SGB within the past 6 months
  • Serious medical or psychiatric conditions other than TBI or PTSD that could affect cognition (e.g., dementia, Parkinson's Disease)
  • Elevated intracranial pressure
  • For TBI, prior history of headache that can explain the headache intensity (i.e., headache not attributable to TBI)
  • Active psychosis or poorly controlled non-injury or PTSD-related psychiatric condition (e.g., bipolar disorder)
  • Poorly controlled medical conditions that could be exacerbated by treatment (e.g., unstable angina)
  • Pregnancy (women of childbearing age who can become pregnant will have to take a pregnancy test)
  • Non-fluency in English (poor generalizability to military and veteran populations, instruments not validated for use or translated in many languages)

Key Trial Info

Start Date :

July 2 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2028

Estimated Enrollment :

175 Patients enrolled

Trial Details

Trial ID

NCT06608277

Start Date

July 2 2025

End Date

April 30 2028

Last Update

August 26 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Anesthesiology Pain Medicine Center

Chicago, Illinois, United States, 60611

2

Walter Reed National Military Medical Center

Bethesda, Maryland, United States, 20889

3

Womack Army Medical Center

Fort Bragg, North Carolina, United States, 28310